Man Group PLC Nuvation Bio Inc. Transaction History

Man Group PLC

$37.6 Billion
Q2 2024

A detailed history of Man Group PLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Man Group PLC holds 110,626 shares of NUVB stock, worth $244,483. This represents 0.0% of its overall portfolio holdings.

Number of Shares

110,626

Previous 260,279 57.5%

Holding current value

$244,483

Previous $947,000 65.89%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $386,104 - $552,219	-149,653 Reduced 57.5%	110,626 $323,000
Q1 2024 May 15, 2024	BUY	$1.46 - $3.97 $32,045 - $87,137	21,949 Added 9.21%	260,279 $947,000
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.53 $228,796 - $364,644	238,330 New	238,330 $359,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $348 - $4,848	1,200 Added 2.23%	55,100 $123,000
Q2 2022 Aug 15, 2022	BUY	$3.24 - $5.85 $127,656 - $230,490	39,400 Added 271.72%	53,900 $175,000
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $66,700 - $128,035	14,500 New	14,500 $76,000

Others Institutions Holding NUVB

# of Institutions

152

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account